Afoxolaner + Moxidectin + Pyrantel

Verify with FDA CVM →

72 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
72
Total Reports
6
Deaths Reported
830.0%
Death Rate

Active Ingredients

AfoxolanerAfoxolaner + Moxidectin + PyrantelMoxidectinPyrantel

Administration Routes

UnknownOral

Species Affected

Dog 70
Unknown 2

Most Affected Breeds

Retriever - Labrador 10
Retriever - Golden 5
Crossbred Canine/dog 5
Shepherd Dog - German 5
Dachshund (unspecified) 4
Chihuahua 4
Beagle 3
Shepherd Dog - Australian 3
Unknown 2
Hound (unspecified) 2

Most Reported Reactions

Lack of efficacy (endoparasite) - heartworm 14
Other abnormal test result NOS 12
Lack of efficacy (endoparasite) - hookworm 10
Vomiting 10
Lethargy (see also Central nervous system depression in Neurological) 9
Diarrhoea 8
Not eating 7
Decreased appetite 6
Lack of efficacy (endoparasite) - tapeworm 6
Elevated serum alkaline phosphatase (ALP) 5
Lack of efficacy - NOS 4
Cough 4

Outcome Breakdown

Outcome Unknown
39 (55.7%)
Ongoing
18 (25.7%)
Recovered/Normal
7 (10.0%)
Died
5 (7.1%)
Euthanized
1 (1.4%)

Data Summary

Metric Value
Total adverse event reports 72
Reports involving death 6
Case-fatality rate (reported events) 830.0%
Distinct species in reports 2
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 4

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Afoxolaner + Moxidectin + Pyrantel Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 72 adverse event reports referencing Afoxolaner + Moxidectin + Pyrantel, including 6 reports in which the animal died — a 830.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredients on file: Afoxolaner, Afoxolaner + Moxidectin + Pyrantel, Moxidectin, Pyrantel. Reported administration routes include Unknown, Oral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Afoxolaner + Moxidectin + Pyrantel reports are Dog (70 reports), Unknown (2 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (10), Retriever - Golden (5), Crossbred Canine/dog (5) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Afoxolaner + Moxidectin + Pyrantel are Lack of efficacy (endoparasite) - heartworm (14), Other abnormal test result NOS (12), Lack of efficacy (endoparasite) - hookworm (10), Vomiting (10). Of the 70 reports with a coded outcome, Outcome Unknown is the leading category at 55.7%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Afoxolaner + Moxidectin + Pyrantel.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial